Functioning as a tumor-suppressive lncRNA, TCL6 curbs the carcinogenic effects of the PI3K/AKT signaling pathway by directly interacting with miR-106a-5p, subsequently upregulating PTEN expression in HCC (Luo et al., 2020). Here, TCL6 is linked to hepatocellular carcinoma.